BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38684838)

  • 21. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology.
    Akuta N; Kawamura Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
    Intern Med; 2020 Aug; 59(16):1931-1937. PubMed ID: 32448832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease.
    Baek JH; Yang YS; Ko SH; Han KD; Kim JH; Moon MK; Park JS; Lee BW; Oh TJ; Chon S; Choi JH; Hur KY
    Diabetes Metab J; 2022 Sep; 46(5):701-712. PubMed ID: 35654585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases.
    Wang L; Voss EA; Weaver J; Hester L; Yuan Z; DeFalco F; Schuemie MJ; Ryan PB; Sun D; Freedman A; Alba M; Lind J; Meininger G; Berlin JA; Rosenthal N
    Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1620-1628. PubMed ID: 31456304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.
    Kim GA; Park Y; Oh SJ; Jung J; Han S; Chang HS; Park SW; Kim TH; Park HW; Choe J; Kim J; Lee HC
    Liver Int; 2024 Mar; 44(3):738-748. PubMed ID: 38110797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.
    Wong C; Yaow CYL; Ng CH; Chin YH; Low YF; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2020; 11():609135. PubMed ID: 33643221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea.
    Hwang HJ; Kim M; Jun JE; Yon DK
    Sci Rep; 2023 Dec; 13(1):21756. PubMed ID: 38066029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Jung C; Park S; Kim H
    PLoS One; 2023; 18(11):e0294423. PubMed ID: 37992029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
    Arase Y; Kobayashi M; Suzuki F; Suzuki Y; Kawamura Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
    Hepatology; 2013 Mar; 57(3):964-73. PubMed ID: 22991257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma.
    Kawamura Y; Arase Y; Ikeda K; Seko Y; Imai N; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ohmoto Y; Amakawa K; Tsuji H; Kumada H
    Am J Gastroenterol; 2012 Feb; 107(2):253-61. PubMed ID: 22008893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychiatric disorders in patients with type 2 diabetes mellitus on sodium-glucose cotransporter-2 inhibitors-a nationwide retrospective cohort study.
    Hu WS; Lin CL
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jan; 397(1):575-581. PubMed ID: 37490120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.
    Tateishi R; Okanoue T; Fujiwara N; Okita K; Kiyosawa K; Omata M; Kumada H; Hayashi N; Koike K
    J Gastroenterol; 2015 Mar; 50(3):350-60. PubMed ID: 24929638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of fasting serum glucose level and type 2 diabetes with hepatocellular carcinoma in men with chronic hepatitis B infection: A large cohort study.
    Kim K; Choi S; Park SM
    Eur J Cancer; 2018 Oct; 102():103-113. PubMed ID: 30189372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-glucose cotransporter 2 inhibitors do not increase the risk of fractures in real-world clinical practice in Korea: A national observational cohort study.
    Ha KH; Kim DJ; Choi YJ
    J Diabetes Investig; 2022 Jun; 13(6):986-996. PubMed ID: 35132815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF; Chen SW; Liu JR; Li PR; Wu LS; Chang SH; Yeh YH; Kuo CT; Chan YH; See LC
    Cardiovasc Diabetol; 2020 Sep; 19(1):160. PubMed ID: 32998736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.
    Yen FS; Wei JC; Yu TS; Hung YT; Hsu CC; Hwu CM
    JAMA Netw Open; 2023 Dec; 6(12):e2348431. PubMed ID: 38117497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer Risk in Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Simon TG; Roelstraete B; Sharma R; Khalili H; Hagström H; Ludvigsson JF
    Hepatology; 2021 Nov; 74(5):2410-2423. PubMed ID: 33811766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia.
    Seko Y; Kawanaka M; Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Okanoue T; Itoh Y; Nakajima A;
    J Gastroenterol Hepatol; 2022 Dec; 37(12):2313-2320. PubMed ID: 36198983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.